Genitourinary Cancers | Specialty

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Pembrolizumab/Axitinib Improves Survival in Frontline RCC

October 19th 2018

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

October 12th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Dr. O'Donnell Compares Checkpoint Inhibitors in Bladder Cancer

October 12th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Dr. Steinberg on Treatment Approaches in Non-Muscle Invasive Bladder Cancer

October 9th 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses treatment approaches in non-muscle invasive bladder cancer (NMIBC).

Dr. Choueiri Discusses the CANTATA Trial in RCC

October 5th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma.

Immunotherapy Continues to Be Integrated in Metastatic Bladder Cancer

October 4th 2018

Peter O’Donnell, MD, discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma

October 3rd 2018

The dismal prognosis for patients with metastatic renal cell carcinoma has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.

Dr. Stadler on Approved and Investigational Therapies in RCC

October 2nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers

October 2nd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Dr. Sweis on the Frequency of Immune-Related Adverse Events in Kidney Cancer

September 28th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Genomics of Bladder Cancer Remain Largely Unknown

September 26th 2018

Joshua J. Meeks, MD, PhD, discusses the current understanding of genomics in bladder cancer.